Exclusive: Tens of millions of J&J COVID-19 shots sit at Baltimore factory

An estimated 30 million to 50 million doses of Johnson & Johnson's (JNJ.N) COVID-19 vaccine made early this year sits idle in Emergent BioSolutions Inc's plant in Baltimore awaiting a green light from U.S. regulators to ship, two sources familiar with the matter said. Emergent, a contract drug manufacturer, is waiting for the U.S. Food and Drug Administration to approve release of those doses. The agency must still inspect and authorize the plant before Emergent can ship newly manufactured drug substance, one of the sources said.